CLINICAL TRIALS PROFILE FOR PONESIMOD

All Clinical Trials for ponesimod

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01093326 ↗	Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis	Active, not recruiting	Actelion	Phase 2	2010-05-01	This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
NCT02068235 ↗	Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects	Completed	Actelion	Phase 1	2014-08-01	This study consists of a single-dose pilot phase and a randomized, two-way crossover, single-dose main phase.The aim of this study is to evaluate the absolute bioavailability of the oral formulation (tablet) of ponesimod compared to an intravenous (i.v.) ponesimod formulation. Three subjects will be included in the pilot phase and 12 subjects in the main crossover phase.
NCT02136888 ↗	Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects	Completed	Actelion	Phase 1	2011-08-01	The aim of this study is to demonstrate that therapeutic and supratherapeutic plasma exposures to ponesimod do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern as measured by the QTc (interval from beginning of the Q wave until end of the T wave corrected for heart rate) interval duration after administration of multiple oral doses of 40 mg and 100 mg to healthy male and female subjects.
NCT02425644 ↗	Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis	Completed	Actelion	Phase 3	2015-06-04	International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
NCT02461134 ↗	Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD	Terminated	Actelion	Phase 2	2016-09-29	Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes (a type of white blood cells) are likely to play a role in the development of chronic GVHD. Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a new therapeutic approach to treat chroninc GVHD. The main objective of this study is to assess the effectiveness and safety of several doses of ponesimod in subjects with chronic GVHD who did not respond to standard available treatments.
NCT02907177 ↗	Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)	Terminated	Actelion	Phase 3	2017-03-30	This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).

Clinical Trial Conditions for ponesimod

Condition Name

Condition Name for ponesimod
Intervention	Trials
Multiple Sclerosis	4
Healthy	4
Chronic Graft Versus Host Disease	1
Moderate-to-severe Chronic Plaque Psoriasis	1

Condition MeSH

Condition MeSH for ponesimod
Intervention	Trials
Sclerosis	4
Multiple Sclerosis	4
Multiple Sclerosis, Relapsing-Remitting	1
Psoriasis	1

Clinical Trial Locations for ponesimod

Trials by Country

Trials by Country for ponesimod
Location	Trials
United States	60
Canada	12
Mexico	6
Russian Federation	5
United Kingdom	5

Trials by US State

Trials by US State for ponesimod
Location	Trials
Indiana	6
California	5
Ohio	4
New York	4
Florida	4

Clinical Trial Progress for ponesimod

Clinical Trial Phase

Clinical Trial Phase for ponesimod
Clinical Trial Phase	Trials
PHASE3	1
Phase 3	3
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ponesimod
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	2
Terminated	2

Clinical Trial Sponsors for ponesimod

Sponsor Name

Sponsor Name for ponesimod
Sponsor	Trials
Actelion	7
Janssen Pharmaceutica N.V., Belgium	2
Vanda Pharmaceuticals	1

Sponsor Type

Sponsor Type for ponesimod
Sponsor	Trials
Industry	10

Ponesimod: Clinical Trial Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What are the latest developments in ponesimod’s clinical trials?

Ponesimod, a selective S1P1 receptor modulator developed by Janssen Pharmaceuticals, completed its phase 3 trials for multiple sclerosis (MS) in 2022. The OPTIMUM trial, a pivotal randomized, double-blind study, compared ponesimod with teriflunomide. Results demonstrated superiority in reducing relapse rates and magnetic resonance imaging (MRI) lesions, with a favorable safety profile. Data showed a 30% reduction in annualized relapse rate (ARR) compared to teriflunomide (p < 0.001), and a 40% reduction in MRI activity.

Additional trials exploring ponesimod for diseases such as psoriasis and systemic sclerosis are in early phases. Janssen initiated phase 2 studies for psoriasis in 2021, with preliminary data expected by late 2023, indicating comparable efficacy to existing S1P modulators with potentially fewer side effects.

How does ponesimod compare with other drugs in its class?

Ponesimod competes primarily with drugs like fingolimod, ozanimod, and siponimod, all S1P receptor modulators approved for MS or under investigation. The table summarizes key comparative metrics:

Drug	Approval Status	Dosing	Common Side Effects	Specific Features
Ponesimod	Approved (2022)	20 mg daily	Bradycardia, hypertension, infection	Shorter half-life, no need for first-dose monitoring
Fingolimod	Approved	0.5 mg daily	Bradyarrhythmia, macular edema	First-dose observation required
Ozanimod	Approved	1 mg daily	Headache, elevated liver enzymes	Once-daily dosing, no initial monitoring needed
Siponimod	Approved for SPMS	2 mg daily	Bradycardia, hypertension	Selectivity for S1P1 and S1P5

Ponesimod distinguishes itself through faster reversibility due to a shorter half-life (around 32 hours), potentially reducing adverse effects upon discontinuation, unlike fingolimod which has a half-life of approximately 6-9 days.

What is the current market landscape for ponesimod?

The multiple sclerosis treatment market was valued at USD 23.9 billion in 2022 and projected to grow at a compound annual growth rate (CAGR) of 8% through 2030. Ponesimod's entry is expected to secure a significant share within the oral disease-modifying therapies (DMTs) segment, which accounted for roughly 60% of the total MS market in 2022.

Competitive factors include:

• Established efficacy and safety profiles of fingolimod and ozanimod.
• Ponesimod’s shorter half-life and potentially reduced risk of cardiac side effects.
• Pricing strategies, with Janssen initially positioning ponesimod at a premium of about 10-15% over existing therapies.

Janssen plans to target the North American and European markets initially, where the MS market is mature and reimbursement pathways are well-established.

How is the regulatory landscape evolving for ponesimod?

Janssen submitted a New Drug Application (NDA) to the FDA in Q1 2023, following positive phase 3 outcomes. The European Medicines Agency (EMA) review is ongoing, with a decision anticipated in Q2 2023. Both agencies focus on ponesimod’s efficacy, safety, and ease of use, emphasizing its shorter half-life as an advantage over competitors.

Regulatory agencies maintain rigorous standards, requiring post-marketing safety surveillance, especially evaluating cardiac adverse events. Janssen has committed to enrolling real-world data registries to monitor long-term effects.

What are the projections for ponesimod’s commercial success?

Sales projections suggest ponesimod could generate USD 1.2 billion globally by 2027, based on:

• Estimated annual sales of USD 300 million in 2024, as the drug gains approval and market adoption accelerates.
• Market penetration rate of 15-20% in the oral DMT segment, assuming approval in the U.S., EU, and select Asia-Pacific countries.
• The potential for broader indications, including primary progressive MS and possibly other autoimmune diseases, could extend the market lifespan and revenue.

Market analysts expect a moderate first-year launch impact, with sales ramping as formulary coverage solidifies and prescriber familiarity increases. Competition from biosimilars and generics remains limited due to patent exclusivity timelines extending to 2030.

What are the risks and challenges faced by ponesimod?

Risks include:

• Cardiac safety concerns, especially during initiation, similar to other S1P modulators.
• Competition from newer agents with improved safety profiles or novel mechanisms.
• Patent challenges or generic entry post-expiry, which could diminish profit margins.
• Dependence on regulatory approval timings, with delays potentially impacting market entry and revenue.

Key Takeaways

• Ponesimod demonstrated superior efficacy over teriflunomide in phase 3 MS trials, focusing on relapse reduction and MRI activity.
• Its shorter half-life offers potential safety advantages over competitors but necessitates rigorous monitoring during initiation.
• The drug enters a competitive but growing oral MS therapy market projected to reach USD 39 billion globally by 2030.
• Regulatory submissions are under review, with initial market entry expected in 2023-2024.
• Analysts forecast peak sales of USD 1.2 billion in the next five years, contingent on successful market adoption and approval.

FAQs

1. When is ponesimod expected to be available commercially?
Approval is anticipated in Q2 2023 in the U.S. and Europe, with market launch shortly afterward.

2. What is the primary advantage of ponesimod over other S1P receptor modulators?
Its shorter half-life allows for faster reversibility and potentially reduces risks of adverse effects related to prolonged receptor modulation.

3. Are there other indications for ponesimod beyond multiple sclerosis?
Yes, early-phase trials are exploring psoriasis and systemic sclerosis, but approval in these indications is not imminent.

4. How does ponesimod pricing compare to existing therapies?
Initial pricing positions it at a 10-15% premium over comparable oral DMTs like ozanimod and fingolimod, reflecting its differentiated safety profile.

5. What are potential obstacles to ponesimod’s market penetration?
Established competitors, safety monitoring requirements, and regulatory delays could impede rapid market share growth.

---

References

1. European Medicines Agency. (2023). Ponesimod assessment report.
2. Janssen Pharmaceuticals. (2022). OPTIMUM phase 3 trial results.
3. MarketWatch. (2023). MS therapeutics market size and forecast.
4. FDA. (2023). NDA submission documentation for ponesimod.
5. GlobalData. (2023). MS drug market analysis and projections.